Zydus Cadila is one of India's leading healthcare companies and a global healthcare provider with strengths all along the pharmaceutical value chain. The group's state-of-the-art manufacturing infrastructure is spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. Of these, five facilities are USFDA approved.

CDRI is a pioneer research organization in the field of biomedical research in India. It has the infrastructure and expertise to develop a drug right from the concept stage to the market.

Alteza healthcare Pvt. Ltd. is newly established company. The company is heaving it's headquarter at Ahmedabad. Currently the company is in process of hiring of every level of employees. Currently we are hiring for ahmedabad district, rajkot district, surendranagar district, bhavnagar district.

Post: Area Manager, Medical Representative

ABOUT AUTHORS:
MHG Dehgan, Satapathy Asis Amitav*
Y.B.Chavan College of Pharmacy,
Dr. Rafiq Zakaria Campus,
Auranagbad-431001 (MS),
*asish.apharma@gmail.com

ABSTRACT
Nasal route for the administration of drugs is used as an alternative route for the systemic availability of drugs restricted to intravenous administration. This is due to the large surface area, porous endothelial membrane, high total blood flow, the avoidance of first-pass metabolism, and ready accessibility. The nasal administration of drugs, including many biotechnological compounds like hormones, vaccines, peptide and protein drugs to give enhanced bioavailability. Many drug delivery methods for nasal availability of liquid, semisolid and solid formulation are investigated to avail the drugs to treat most CNS diseases (i.e., Parkinson’s disease, Alzheimer’s disease, Migraine attack) because it requires rapid and/or specific targeted delivery of drugs to the brain.
In this review we discuss some factors affecting nasal absorption, bio-availability barriers, and strategies to improve nasal absorption, new developments in nasal dosage form design and applications of nasal drug delivery system and the effects of microspheres, liposomes and other bioadhesive drug delivery systems on nasal drug absorption.

EPIDermizz, a skincare division of Nippon Seiyaku Pvt. Ltd. Nippon Seiyaku Pvt. Ltd. is an associate of Nippon Seiyaku co. Ltd., Japan which have been started its operation in Indian Market in 2001. Having robust brand NUTRIFACTS, Nippon is one of the most admired companies in pediatric fraternity. It has the history of pioneering in the area of nutrition by launching molecules like Methylcobalamine, Benfothiamine and Co Enzyme Q10 first time in India.

Virchow Biotech Private Limited (VBPL), an innovative biotechnology company headquartered at Hyderabad, India. VBPL also has offices located in the United States of America ( at Nashville, Tennessee)

Abbott India Limited is a subsidiary of Abbott Laboratories, USA, a global, iversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company now employs approximately 70,000 people and markets its products in 130 countries worldwide.

The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia.

NIMS Institute of Pharmacy is approved by AICTE (All India Council for technical Education), Government of India. It offers undergraduate, postgraduate and Ph. D. programmes. The Institute has its separate building in the campus with spacious well equipped laboratories for each discipline and specialization. Pharma D. course has been designed on the lines of some universities in USA.

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. The company’s products and services are designed to benefit people and improve their quality of life.

Wockhardt today, is distinguished by a strong and growing presence in the world's leading markets, with more than 65% of its revenue oming from Europe and the United States. Wockhardt's market presence covers formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).

About Authors:
KALPESH PATEL, JAYACHANDRAN E.*, SREENIVASA G.M.
* P.G. Department of Pharmaceutical Chemistry,
S.C.S. College of Pharmacy, Harapanahalli-583131,
Karanataka, India.
*drjc_2006@rediffmail.com, kalpesh.m.pharm@gmail.com

Abstract
Various substituted 3-amino-1-(2,4-dinitro phenyl)-5-[(5-substituted-1,3,4-oxadiazol-2-yl)amino]-1-H-pyrazole-4-carboxyamide and (5E)-5-[4-(dimethylamino) benzylidene]-3-(5-substituted-1,3,4-oxadiazol-2-yl)-2-phenyl-3,5-di hydro-4H-imidazol-4-one have been synthesised and evaluated for antiinflammatory activity. Structure of these products has been established by IR, ¹H NMR data. Significant activity were observed for some members of the series.

National Institute for Research in Reproductive Health (NIRRH), formerly known as Institute for Research in Reproduction is a premier research institute of the Indian Council of Medical Research (ICMR). It is situated in the vicinity of a number of hospitals and research institutes in central Mumbai.

Troikaa mainly focuses on Novel Drug Delivery Systems (NDDS). The company firmly believes in providing superior therapeutic benefits by improvising the formulations through Innovative Technologies.
Six patents have been filed in various areas of drug delivery. To handle competition, Troikaa adopted various multifaceted strategies to help stand their ground in the competitive market. Another fact that helps us stand out is their high quality products.

With USFDA approvable API facility - Mac-Chem has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. The paradigm shift of leading Indian pharmaceutical companies to target low volume and blockbuster products for regulated markets has been the inspiration behind the launch.